Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension
- Authors
- Byun, Jung-Ick; Moon, Jangsup; Kim, Do-Yong; Shin, Hyerim; Sunwoo, Jun-Sang; Lim, Jung-Ah; Kim, Tae-Joon; Lee, Woo-Jin; Lee, Han Sang; Jun, Jin-Sun; Park, Kyung-Il; Lee, Soon-Tae; Jung, Keun-Hwa; Jung, Ki-Young; Lee, Sang Kun; Chu, Kon
- Issue Date
- 5-Sep-2017
- Publisher
- Lippincott Williams & Wilkins Ltd.
- Keywords
- orthostatic hypotension; Midodrine; Pyridostigmine
- Citation
- Neurology, v.89, no.10, pp 1078 - 1086
- Pages
- 9
- Journal Title
- Neurology
- Volume
- 89
- Number
- 10
- Start Page
- 1078
- End Page
- 1086
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/7219
- DOI
- 10.1212/WNL.0000000000004340
- ISSN
- 0028-3878
1526-632X
- Abstract
- Objective: To evaluate the long-term (for up to 3 months) efficacy and safety of single or combined therapy with midodrine and pyridostigmine for neurogenic orthostatic hypotension (OH). Methods: This was a randomized, open-label clinical trial. In total, 87 patients with symptomatic neurogenic OH were enrolled and randomized to receive 1 of 3 treatments: midodrine only, pyridostigmine only, or midodrine 1 pyridostigmine. The patients were followed up at 1 and 3 months after treatment. The primary outcome measures were improvement in orthostatic blood pressure (BP) drop at 3 months. Secondary endpoints were improvement of the orthostatic BP drop at 1 month and amelioration of the questionnaire score evaluating OH-associated symptoms. Results: Orthostatic systolic and diastolic BP drops improved significantly at 3 months after treatment in all treatment groups. Orthostatic symptoms were significantly ameliorated during the 3-month treatment, and the symptom severity was as follows: midodrine only, midodrine 1 pyridostigmine, pyridostigmine only group. Mild to moderate adverse events were reported by 11.5% of the patients. Conclusions: Single or combination treatment with midodrine and pyridostigmine was effective and safe in patients with OH for up to 3 months. Midodrine was better than pyridostigmine at improving OH-related symptoms. Clinicaltrials. gov identifier: NCT02308124. Classification of evidence: This study provides Class IV evidence that for patients with neurogenic OH, long-term treatment with midodrine alone, pyridostigmine alone, or both midodrine and pyridostigmine is safe and has similar effects in improving orthostatic BP drop up to 3 months.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Neurology > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/7219)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.